Magnesium supplementation did not reduce serum calciprotein crystallization and arterial stiffness in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Meer R, Xu JY, Newsom SP, Pasch A, Vervloet MG, de Jong PA, Elders PJ, Beulens JW
The American journal of clinical nutrition · 0 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Amsterdam University Medical Centers
- Gobierno
- ZonMw
- Gobierno
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Autores
- Al menos un autor declara un vínculo económico con la industria
- Subvenciones
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (91 71 8304); ZonMw (91718304)
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-03-26 · Am J Clin Nutr · vol. 123 · número 5 · pág. 101299
- Editorial
- Elsevier BV
- Citado
- 0 citas · más que el 16% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 47 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Magnesium in Health and Disease · Cardiovascular Health and Disease Prevention · Dermatological and Skeletal Disorders
- Palabras clave
- magnesium supplementation, magnesium citrate, type 2 diabetes, medial arterial calcification, arterial stiffness, pulse wave velocity, carotid-femoral pulse wave velocity, peripheral arterial calcification, urinary magnesium excretion, serum magnesium, cardiovascular risk, nephelometry, 24-hour urine collection, 24-hour urine calcium
- MeSH
- humans, diabetes mellitus, type 2, magnesium, magnesium compounds, citric acid, organometallic compounds, crystallization, double-blind method, dietary supplements, aged, female, male, vascular stiffness, vascular calcification, pulse wave analysis
8 autores
- Romain Meer🇳🇱 · autor de correspondenciaAmsterdam University Medical Centers; Amsterdam Cardiovascular Sciences
- Joyce Xu🇳🇱Amsterdam University Medical Centers; Amsterdam Cardiovascular Sciences
- Simon P Newsom🇳🇱Amsterdam University Medical Centers
- Andreas Pasch🇦🇹Johannes Kepler University of Linz
- Marc G. Vervloet🇳🇱Radboud University Medical Center; Amsterdam Cardiovascular Sciences
- Pim A. de Jong🇳🇱University Medical Center Utrecht
- Petra J. M. Elders🇳🇱Amsterdam Public Health; Amsterdam University Medical Centers
- Joline W. J. Beulens🇳🇱University Medical Center Utrecht; Amsterdam Public Health; Amsterdam University Medical Centers; Amsterdam Cardiovascular Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Medial arterial calcification (MAC) and increased arterial stiffness contribute to cardiovascular disease risk in type 2 diabetes mellitus (T2DM). Experimental studies suggest that magnesium supplementation may halt arterial calcification and improve arterial stiffness.
Objectives
This study aimed to evaluate the effect of 6-mo oral magnesium citrate supplementation on calciprotein crystallization (T50) and carotid-femoral pulse wave velocity (cfPWV) in individuals with T2DM and peripheral MAC.
Methods
This double-blind, placebo-controlled trial randomly assigned 74 participants with T2DM [78% males, 72 (68-76) y] with peripheral MAC and cfPWV≥12.0 m/s to magnesium citrate (350 mg/d; n = 37) or placebo (n = 37). Nephelometry-based T50 measurements, cfPWV measurements, and 24-h urine collections were obtained at baseline, 3 and 6 mo. Longitudinal analysis of covariance adjusted for baseline T50 and cfPWV was used to study the treatment effects on T50 and cfPWV.
Results
Baseline mean T50 and cfPWV were similar between the magnesium group (T50 348 ± 54 min; cfPWV 15.9 ± 2.2 m/s) and the placebo group (362 ± 54 min; 15.6 ± 2.0 m/s). Magnesium in serum and in 24-h urine were lower in the magnesium group [0.74 (0.71-0.77) mmol/L and 3.30 (2.06-4.71) mmol/24 h] compared with the placebo group [0.81 (0.74-0.86) mmol/L and 4.31 (3.09-5.54) mmol/24 h]. Supplementation increased 24-h urine magnesium excretion (P 50 [ẞ = 6 min (-11, 22), P = 0.491] but did increase cfPWV [ẞ = 0.8 m/s (0.1, 1.5), P = 0.021] over 6 mo in the magnesium group relatively to the placebo group, but the statistical significance was lost after adjusting for clinically relevant baseline differences [T50: ẞ = 7 min (-12, 25), P = 0.482; cfPWV: ẞ = 0.5 m/s (-0.2, 1.3), P = 0.180].
Conclusions
Six-month magnesium citrate supplementation did not reduce calciprotein crystallization and arterial stiffness in older individuals with T2DM with peripheral MAC. Daily supplementation of 350 mg appears to be ineffective in this population, possibly attributable to normomagnesemia and preserved renal function. This study was registered at the Dutch Trial Register (CCMO) as NL81281.029.22 and at ISRCTN as 60460377.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.